生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | The epidermal growth factor receptor (EGFR) tyrosine kinase was one of the first receptor tyrosine kinases to be targeted for drug development by the pharmaceutical industry due to its ubiquitous overexpression in a variety of tumors. EGFR Inhibitor is a highly selective inhibitor of the EGFR with an IC50 of 21 nM against EGFR kinase in vitro and blocks receptor autophosphorylation in cells. It exhibits exclusive selectivity against EGFR at a concentration of 10 μM and potently inhibits two EGFR mutants associated with clinical response to gefitinib: L858R (IC50 = 63 nM) and L861Q (IC50 = 4 nM). Treatment of U-2OS cells transfected with WT EGFR with epidermal growth factor (EGF) resulted in receptor autophosphorylation. Pretreatment of cells with EGFR Inhibitor (10 μM) resulted in complete inhibition of WT receptor autophosphorylation. This result was also evident from the observation that greater levels of receptor were immunoprecipitated from compound-treated compared to untreated cells, consistent with reports that EGFR activation leads to its rapid degradation[1]. | ||
作用机制 | The selectivity of EGFR Inhibitor is derived from the ability to form three hydrogen bonding interactions while occupying a hydrophobic cavity made accessible due to the small gatekeeper threonine 766[1]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.42mL 0.48mL 0.24mL |
12.09mL 2.42mL 1.21mL |
24.19mL 4.84mL 2.42mL |
参考文献 |
---|